NCT04188015View on ClinicalTrials.gov

Study of ANX007 in Participants With Primary Open-angle Glaucoma

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 25, 2018

Primary Completion Date

June 3, 2019

Study Completion Date

June 3, 2019

Conditions
Open Angle Glaucoma
Interventions
BIOLOGICAL

2.5mg ANX007

A single dose of 2.5mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.

BIOLOGICAL

5.0mg ANX007

A single dose of 5.0mg ANX007 will be administered via IVT injection into the study eye at Day 1 and Day 29.

OTHER

Sham Procedure

The sham injection is preformed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of a syringe without a needle.

Trial Locations (2)

94303

Eye Research Foundation, Newport Beach

94305

Stanford Health Care, Stanford

All Listed Sponsors
lead

Annexon, Inc.

INDUSTRY

NCT04188015 - Study of ANX007 in Participants With Primary Open-angle Glaucoma | Biotech Hunter | Biotech Hunter